Skip to main content
. Author manuscript; available in PMC: 2013 Sep 10.
Published in final edited form as: Dev Biol. 2009 Jun 22;333(1):26–36. doi: 10.1016/j.ydbio.2009.06.019

Figure 5. Dazap2 gain-of-function expands the neural plate and induces a posterior identity at the expense of anterior fates.

Figure 5

Injections of dazap2 mRNA were targeted either dorsally (A’-H’, red arrow) or ventrally (A”-E”, green arrow). Embryos were analyzed at stage 16–18 (shown in dorsal views with anterior at the top (A–E”), or frontal views (F–H’)). The injected side is on the right, injected cells are marked by the red nuclear stain). General neural markers nrp1 (A–A”), sox2 (B–B”) and sox11 (C–C”) are expanded when Dazap2 is expressed in or around the neural plate but not when dazap2 is injected on the ventral side of the embryo. MyoD (D–D”) expression is not effected by either dorsal or ventral injections. Hoxb9 (E–E”) is strongly ectopically expressed in dorsal but not ventral targeted injections. The expression of anterior neural markers cpl1 (F, F’) and pax6 (G, G’) is decreased when dazap2 is targeted to the anterior neural plate (arrows, bar indicates the midline).